ScholarLens Back to search
2009•Current Opinion in Pulmonary MedicineRequires access

Treatment options for malignant pleural effusion

Ali I. Musani

Open publisher page 74 citations

Abstract

PURPOSE OF REVIEW: Thirty percent of lung cancers eventually result in malignant pleural effusion (MPE). Devastating consequences of MPE, such as dyspnea and cough, severely deteriorate the quality of life of these patients. Malignant pleural effusion portends a dismal prognosis of less than 6-month longevity, with the exception of breast and ovarian cancer. Given the poor prognosis of the majority of these patients, palliation, rather than cure, should be the goal of therapy. RECENT FINDINGS: Chest tube insertion and sclerotherapy remain the standard of care. Emerging therapeutic options such as medical pleuroscopy and indwelling pleural catheters offer cost-effective and outpatient treatments for MPE. SUMMARY: In the following review, the medical, economic, and social aspects of different current options for the management of MPE are discussed.

About this research paper

What this paper is about

PURPOSE OF REVIEW: Thirty percent of lung cancers eventually result in malignant pleural effusion (MPE). Devastating consequences of MPE, such as dyspnea and cough, severely deteriorate the quality of life of these patients. Malignant pleural effusion portends a dismal prognosis of less than 6-month longevity, with the exception of breast and ovarian cancer. Given the poor prognosis of the majority of these patients, palliation, rather than cure, should be the goal of therapy. RECENT FINDINGS: Chest tube insertion and sclerotherapy remain the standard of care. Emerging therapeutic options such as medical pleuroscopy and indwelling pleural catheters offer cost-effective and outpatient treatments for MPE. SUMMARY: In the following review, the medical, economic, and social aspects of different current options for the management of MPE are discussed.

Why it matters

OpenAlex reports 74 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

PURPOSE OF REVIEW: Thirty percent of lung cancers eventually result in malignant pleural effusion (MPE). Devastating consequences of MPE, such as dyspnea and cough, severely deteriorate the quality of life of these patients. Malignant pleural effusion portends a dismal prognosis of less than 6-month longevity, with the exception of breast and ovarian cancer. Given the poor prognosis of the majority of these patients, palliation, rather than cure, should be the goal of therapy. RECENT FINDINGS: Chest tube insertion and sclerotherapy remain the standard of care. Emerging therapeutic options such as medical pleuroscopy and indwelling pleural catheters offer cost-effective and outpatient treatments for MPE. SUMMARY: In the following review, the medical, economic, and social aspects of different current options for the management of MPE are discussed.

Key concepts: Medicine, Malignant pleural effusion, Pleural effusion, Intensive care medicine, Quality of life (healthcare), Pleurodesis, Lung cancer, Surgery

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Treatment options for malignant pleural effusion — Research Paper | ScholarLens